DDInter511 DDInter899
Desvenlafaxine (O-desmethylvenlafaxine) is the 0-demetyhlated active metabolite of [venlafaxine]. Like its parent drug, desvenlafaxine is also an antidepressant belonging to the class of serotonin-norepinephrine reuptake inhibitor (SNRI) class.[A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. Although the exact mechanism of pathophysiology is still unknown, imbalances or deficiencies of monoamines have been heavily implicated, thus the rationale behind the use of SNRI to treat MDD. Desvenlafaxine has a very similar pharmacological, efficacy, and safety profile as [
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Desvenlafaxine {u} (Compound) resembles {v} (Compound) Cyclopentolate
Desvenlafaxine {u} (Compound) binds {v} (Gene) SLC6A2
Desvenlafaxine {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Desvenlafaxine {u} (Compound) causes {v} (Side Effect) Hot flush
Desvenlafaxine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cimetidine
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Sodium sulfate
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Urea
Desvenlafaxine {u} may lead to a major life threatening interaction when taken with {v} Dextromethorphan
Desvenlafaxine {u} may lead to a major life threatening interaction when taken with {v} Methylene blue
Desvenlafaxine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v} Iobenguane
Desvenlafaxine (Compound) resembles Cyclopentolate (Compound)
Desvenlafaxine (Compound) binds SLC6A2 (Gene)
Desvenlafaxine (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Desvenlafaxine (Compound) causes Hot flush (Side Effect)
Desvenlafaxine may cause a minor interaction that can limit clinical effects when taken with Cimetidine
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Urea
Desvenlafaxine may lead to a major life threatening interaction when taken with Dextromethorphan
Desvenlafaxine may lead to a major life threatening interaction when taken with Methylene blue
Desvenlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Desvenlafaxine may lead to a major life threatening interaction when taken with Iobenguane